Navigation Links
Quincy Bioscience Launches HOPETrials.com; Research Studies More Accessible For Participants
Date:5/13/2010

Quincy Bioscience announces the launch of HOPETrials.com – a new portal aimed at making research studies of the jellyfish protein apoaequorin accessible for individuals with debilitating conditions. People are encouraged to visit the site to learn about study recruitment. HOPE Trials is the research arm of Quincy Bioscience.

Madison, WI (Vocus) May 13, 2010 -- Quincy Bioscience announces the launch of HOPE Trials.com – a new portal aimed at making research studies of the jellyfish protein apoaequorin accessible for individuals with debilitating conditions. HOPE Trials is the research arm of Quincy Bioscience.


The mission of HOPE Trials is to improve the quality of life for individuals suffering from an array of debilitating conditions such as Alzheimer’s disease and Parkinson’s disease linked by a common cause – a mismanagement of calcium at the cellular level. By bringing research studies into the homes of individuals living with neurodegenerative diseases, researchers are able to achieve larger numbers of participants and improve the quality of data gathered.

Quincy Bioscience research to date has shown the effectiveness of the jellyfish protein apoaequorin to improve cognitive function and other quality of life measures in generally healthy individuals. With the development of the HOPE Trials website and the implementation of clinically-validated rating scales, researchers at Quincy Bioscience will be able to gain better understanding on how this jellyfish protein may help improve the lives of those with neurological conditions.

Mark Underwood, co-founder and president, stresses the importance of both high quality and real world research, “HOPE Trials represents an innovation in research by delivering survey tools directly to participants. Two of the main reasons people choose not to take part in conventional clinical studies are the amount time and travel required. HOPE Trials greatly reduces these demands while gathering important data using the gold standard in research, randomized controlled trials.” explains Underwood.

Maximizing the use of the Internet and social media to help recruitment, HOPE Trials will access a larger demographic of people, and strengthen research. HOPE Trials has begun recruiting for the MS HOPE Trial. Interested parties can visit HOPE Trials.comto find out if they qualify to participate and learn more about future studies.

About Quincy Bioscience
Quincy Bioscience is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the aging process. The company's products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms.

###

Read the full story at http://www.prweb.com/releases/hopetrials/research/prweb4001614.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Southridge LLC Provides Equity Capital Through Private Agreement with PuraMed Bioscience
2. Euthymics Bioscience Collaborates with GlobalSign and SafeNet to Provide an FDA Approved Electronic Signature Solution
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2009 Financial Results
4. Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services
5. Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
6. Thriving Bioscience Region Leaves Its Mark
7. Online Candy Store BW Clifford Launches New Candy Lines and Industry News Resources
8. VoIP Supply Launches Video Conferencing Solutions
9. GMARK Launches World's First Web-Like, PowerPoint Navigation Software
10. Skincancer.com Launches With Latest News, Information and Help for Consumers/Patients and Physicians
11. Capture Medical Billing Launches Facebook Fan Page to Help Improve Medical Billing Issues
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Quincy Bioscience Launches HOPETrials.com; Research Studies More Accessible For Participants
(Date:12/8/2016)... ... , ... David J. Dykeman , Ginger Pigott , and ... at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg ... global Life Sciences & Medical Technology Group have been featured speakers at every DeviceTalks ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... 10.2 version gives development continuity to its innovative Unified Instance Manager architecture, ... capacity. In addition, this new version optimizes the unattended auto-dialing system without ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to ... convenient service for Texas, they are expanding their presence in Dallas. One of the ... that will bring new jobs to the Dallas and Forth Worth market. STAT takes ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and the Affordable Care Act. Dr. Botelho advocates for the mass media launching ... movement gives people ongoing opportunities to share their unfortunate experiences; such a movement ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ... from offices headquartered in Hamilton County, is embarking on a charity drive with ... in finding new homes for orphaned or neglected senior dogs in the Cincinnati ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016 Australia Glaucoma Surgery Devices ... new report, "Australia Glaucoma Surgery Devices Market Outlook ... Australia Glaucoma Surgery Devices market. The report provides ... units) and average prices (USD) within market segement ... provides company shares and distribution shares data for ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... to grow in 2017-2023. Various reasons for growth of ... population, higher incidences of chronic diseases, high recovery cost ... aid services. Medical lifting sling refers to an ... limited mobility. These slings connect to the lift and ...
(Date:12/8/2016)... Dec. 8, 2016  Eli Lilly and Company (NYSE: ... its phase 3 EXPEDITION3 trial at the 9 th ... previously disclosed, solanezumab did not meet the primary endpoint ... initiated in people with mild dementia due to Alzheimer,s ... for solanezumab for the treatment of mild dementia due ...
Breaking Medicine Technology: